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Positron Emission Tomography (PET) is a powerful and non-invasive imaging
technique used for human and animal organ imaging. Currently, the market for PET is
project to reach $5.4 billion per year by 2015.5 This research focuses on the direct
incorporation of [18F]-fluoride into PET ligands. The widespread use of PET imaging is
currently frustrated, in part, by the lack of efficient fluorination chemistry.
Glutamate, one of the 20 most abundant naturally occurring amino acids, serves
as a neurotransmitter in the central nervous system. Glutamate functions in this capacity
by binding to ionotropic and metabotropic receptors. Metabotropic receptors are Gcoupled proteins that are involved in many disorders such as Parkinson’s disease, anxiety,
depression and addiction. This research focuses on the preparation of PET ligands for the
mGluR5 subtype receptor.

3-fluoro-5-(pyridin-2-ylethynyl)benzonitrile

(PEB)

and

3-fluoro-5-((6-

methylpyridin-2-yl)ethynyl)benzonitrile (MPEB) are the two of the drugs of interest for
this research. Previously reported

18

F-radiolabeling techniques for the preparation of

compounds of this class involved a halogenated precursor with KF in DMSO and using
microwave heating. This strategy yielded approximately 4% RCY (“RCY” in this thesis
refers to decay-corrected yield). We chose this class of compounds as a target because it
provides an opportunity to develop synthetic [18F]-fluoride methodology to make this
drug widely available for neuroscience and neuromedicine.
This method developed here for fluorination of aromatic rings can be expanded to
achieve incorporation of

18

F into aromatic amino acids. Amino acids have been known

to target tumor cells specifically.

In conclusion, this newly developed fluorination

methodology opens a door to a variety of compounds that can be used for PET imaging
studies.
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CHAPTER ONE
Positron emission tomography (PET) is a non-invasive imaging technique used to
visualize physiological and biological processes in real time.1 Compounds are tagged
with a radioactive isotope, allowed to diffuse to the appropriate biological target and
pinpointed by determining the source of the emitted radiation. Figure 1 shows commonly
used PET radiotracers and their uses.

Figure 1. Commonly used radiotracers for PET imaging.1
In PET, the radionuclide label decays by emitting a positron, a positively charged
particle of negative mass. The positron is emitted with significant kinetic energy, but it
slows down within ~ 1 mm as it collides with an electron, after which it annihilates an
electron. This matter-antimatter reaction produces two gamma rays (-rays) emitted at
180o, as shown in Figure 2. The gamma-rays are detected by a scintillation detector, and
the simultaneity of the detection events is used to determine the path of the emitted
gamma ray. Localization of the drug is determined by counting the number of rays
passing through various regions of the space within the detector. Because PET provides
no structural information, images are often coupled with a CT scan to give physiological
landmarks.

11

A.

B.

Figure 2. PET imaging. A. Schematic diagram showing the process and apparatus
for collecting a pet scan. Modified from Nature Reviews, 4, June 2004, 457-469. B.
Cartoon showing the nuclear processes leading to the production of gamma rays.
Several radioactive isotopes used for PET imaging are listed in Table 1. The most
commonly used radionuclides are

11

C,

13

N,

15

O and

18

F.2

These radionuclides are

desirable for radiopharmaceuticals because they are easy to incorporate into ligands
without perturbing significantly the ligand’s affinities for their biological receptors.

11

C

appears to be an excellent candidate for PET imaging. However, the extremely short
half-life (20.4 minutes), severely constrains the types of synthetic reactions that can be
used to introduce it.
counterintuitive;

13

While using a radionuclide with a short half-life seems

N (10 min) and

15

O (2 min), have been applied to PET-based

monitoring of myocardial blow flood and cerebral blood flow, respectiviey.3 Some
advantages of using a short half-life radionuclide are that the overall dose exposure of

12
both patient and clinicians are low, and allows for repeat imaging experiments to be
performed in a single day without requiring a patient to stay overnight at a hospital.
18

18

F-Fluorine is in some sense an ideal radioactive isotope for PET imaging.

Fluorine has a half-life (110 min) that allows for moderately complex synthetic

transformations to be performed. The half-life is sufficiently long to permit even a
multistep synthesis, while still providing a highly radioactive compound. The half-life is
sufficient to allow transportation of the drug to a clinical setting away from the original
cyclotron laboratory. Another reason that

18

F is such an attractive candidate for PET

imaging is due to the emitting of low energy positron upon decay (0.64 MeV), the
positron (+) travels a short distance before it is annihilated (~ 1 mm).
Isotope

Half-life Maximum Mode of
Energy
Decay
(MeV)
(%)

Theoretical
Specific
activity
(GBq/umol)
6.3 x 104

 + (97%)
EC (3%)
11
20.3 min 0.97
3.4 x 105
C
+ (99%)
13
10 min
1.20
7.0 x 105
N
+ (100%)
15
2 min
1.74
3.4 x 106
O
+ (100%)
76
16 hrs
4.0
7.2 x 103
Br
+ (57%)
EC (43%)
124
41.8
2.14
1.15 x 103
I
+ (25%)
days
EC (75%)
68
68.1 min 1.90
1.02 x 105
Ga
+ (89%)
EC (11%)
64
12.7
hrs
0.655
9.13 x 103
Cu
+ (19%)
EC (41%)
+ (40%)
Table 1. Properties of Commonly Used Positron-Emitting Radionuclides3
18

F

110 min

0.64

Structurally, fluorine is advantageous to incorporate into molecules of interest. In
chemical transformations, fluorine can be used to replace a hydrogen; although it may be
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more advantageous to replace an oxygen or a hydroxyl group. Fluorine and oxygen are
sterically similar with Van der Waals radii of 1.52 and 1.47, respectively.1 Fluorine and
oxygen are more electronically similar than fluorine and hydrogen; with electronegativity
scores of 2.20 (H), 3.44 (O) and 3.98 (F).1 Although in some cases changing the polarity
of a bond (C-H to C-F) can increase the potency of the drug.4
Currently, the dollar value of the PET market is projected to reach $5.4 billion in
Europe and the United States by 2015.5
1.2 Metabotropic Glutamate Receptors
L-Glutamate is a major excitatory neurotransmitter in the central nervous system
(CNS). Glutamate is regulated by two types of glutamate receptors; ionotropic and
metabotropic. These two protein receptors can be further categorized into two types
based upon their mechanisms of action.6 Ionotropic glutamate receptors are ligand-gated
ion channels.6 The ion channels allow the transport of K+, Na+ and Ca2+. The flow of
cations causes the neuron to become polarized and send signals down the neuron.
Metabotropic glutamate receptors (mGluR) are G-coupled protein receptors; this receptor
type is responsible for modulation of synaptic transmission.7

This family includes

GABAb, pheromone, and Ca2+ sensing receptors.
There are eight members (mGluR1-8) of the mGluR family.

These eight

proteins are distinguished on the basis of their sequence homology, second messenger
coupling, and pharmacology. Group I (mGluR1 and mGluR5) couple via an alpha Gprotein (Gq/G11) to phospholipase C.8,11 Phospholipase C is an enzyme that is involved
in hydrolysis of phospholipids into diacylgylcerol and the corresponding phosphorylated

14
head group. The mechanism of this biochemical response begins with binding of
glutamate to the receptor which catalyzes GTP-GDP exchange on the associated G
protein; this energy transfer activates the G protein.

The activated G protein then

activates a specific membrane bound phospholipase C (PLC). PLC catalyzes production
of two secondary messenger molecules: diacylglycerol and inositol 1,4,5-trisphosphate
(IP3).7

IP3 binds to receptors on the endoplasmic reticulum and causes Ca2+ to be

released.7 Group II (mGluR2 and mGluR3) and group III (mGluR4, 6, 7, 8) couple to a
heterotrimeric G-protein (Gi/Go) to inhibit adenylyl cyclase activity.6 Andenylyl cyclase
catalyzes the production of cAMP from ATP.

Most mGluR5s are located in the

mammalian CNS and glial cells. Group I is mainly located in a postsynaptic portion of
the neuron, while groups II and III are found in the presynaptic part of the neuron and
their main function is control of neurotransmitter release.
A large, extracellular bi-lobed N terminal domain, characteristic of all mGlu
receptors, is tethered with a cysteine-rich region.9 The cleft between the bi-lobed regions
is the glutamate binding site.

The N-terminal domain is tethered to the seven

transmembrane helical domain, that is anchored to the membrane. Glutamate binds to the
extracellular bi-lobed domain.

The seven transmembrane helical domain contains

binding sites for noncompetitive positive and negative allosteric ligands.

A

noncompetitive ligand is defined as one that does not bind at the same site as the
endogenous glutamate, and therefore does and there for does not compete directly with
glutamate.

15

Figure3.9 Cartoon of an mGlu receptor.
On the basis of the widespread distribution of mGluR5 throughout CNS,
particularly in regions that play essential roles in motor coordination and movement, it is
thought that dysfunction of these receptors is implicated in neurological diseases,
including anxiety, epilepsy and Alzheimer’s.10 For example, Parkinson’s is linked to an
overexpression of mGluR5, so it is believed that inhibiting this receptor may offer an
opportunity for treatment of this disease.10

Currently, several pharmaceuticals

companies(Pfizer, Eli Lilly & Co, and Novartis) are exploring Parkinson’s therapeutic
drug discovery efforts featuring mGluR5 as the target receptor.9
1. 3 mGluR5 Antagonists
Glutamate, the endogenous ligand for mGluR5, is actually a poor starting point
for developing a specific PET imaging agent because glutamate binds to ionotropic and
metabotropic receptors, and would not have receptor specificity. Research was focused
on noncompetitive antagonists of mGluR5. These types of compounds are advantageous
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due to the fact they will not compete with endrogenous glutamate and not decrease the
ligand-receptor sensitivity.10 Figure 4 shows noncompetitive mGluR5 antagonists.

Figure 4. Noncompetitive mGluR5 antagonists
High throughput screening of a compound library yielded the first noncompetitive
mGluR5 antagonists in 1999. This work was performed by Mark Varney at SIBIA
Neurosciences, gave the compounds SIB1757 and SIB1892, shown in Figure 4.12
These compounds are selective, noncompetitive antagonists, and do not bind to the
glutamate receptor site in the N-terminal region of the receptor. This binding property
helps make these compounds more selective for the mGluR5. SIB1757 and SIB1892
were used as a starting point for medicinal chemistry. It was determined that replacement
of the double bond between the aromatic rings with a triple bond yielded higher
antagonist activity.10 These new structures, MPEP and MTEP do not resemble glutamate
at all, feature appropriate lipophility, and have good blood-brain barrier permeablilty.10
With an appropriate set of mGluR5 antagonists identified, PET could be used to
image glutamate receptor distribution in the brain. Efforts were put toward heteroaryl
acetylenes labeled with

18

F or 11C. Figure 5 shows the insertion of radioactive nuclides
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into targets reported to have the best binding profile for PET imaging studies.10 Two
compounds that are of interest to the DiMagno lab are 3-fluoro-5-(pyridin-2ylethynyl)benzonitrile (PEB) and 3-fluoro-5-((2-methylthiazol-4-yl)ethynyl)benzonitrile
(MTEB).

[18F]-PEB is sufficiently lipophilic to cross the blood brain barrier, with a

LogD (lipophilicity coefficient) value of 2.8.

A LogD value between 2 and 3 is

considered optimal for penetration of a compound in the brain.10 [18F]-PEB is extremely
potent; the ki value for the mGluR5 protein is 0.2 nM.

A metabolism study was

performed on [18F]-PEB and showed that 78% of the injected radioactivity (decay
corrected) was found in the brain 30 minutes after administration of the radiotracer.

Figure 5.PET radioligands for the mGluR5 subtype receptor.
The biochemistry of PEB has been investigated extensively.14,15 The precursors
to the radioactive drug ([18F]-PEB) have been synthesized in high yields, but currently
employed fluorination techniques have produced [18F]-labeled PEB and MTEB in only 4
± 0.9% and 4 ± 0.6%, respectively.13 In PEB and MTEB we have clearly identified,
potentially valuable radioligands for PET neuroimaging, but there are no effective
synthetic methodologies for preparing them.

This thesis describes my approach to

preparing these compounds using novel diaryliodonium salt precursors.
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CHAPTER TWO
2.1 Possible Fluorination Techniques
Approximately one third of all currently prescribed pharmaceuticals contain at
least one fluorine atom. Most often fluorine substituents are incorporated to control drug
catabolism from cytochrome p450 activity.

Fluorination of oxidatively sensitive

aromatic rings is a particularly common tool of the trade to enhance lifetime. Typical
fluorination methods require harsh conditions which are not compatible with many
functional groups; to utilize these methods scientist install the fluorine substituents early
in the synthesis. Some traditional methods to fluorinate aromatic rings include BalzSchiemann (B.S) and nucleophilic substitution (SnAr) of electron-deficient arylhalides
with KF.15 The Balz-Schiemann reaction converts aryl amines to aryl fluorides, via a
diazonium salt intermediate. Preparatory of the aryl diazonium salt typically requires
acidic conditions, which may be problematic with particular functional groups.

For

synthesis of PET radiotracers, incorporation of [18F] fluoride must be performed toward
the end of the synthesis because the short half-life of the isotope (110 min) precludes
time consuming, multistep procedures subsequent to fluorination.

Some new

methodologies have been developed recently that describe late stage introduction of
fluoride into electron-rich aromatic rings.
One possible method to increase the fluorination yield is to utilize transition metal
catalysts, specifically palladium.

Figure 5 shows a proposed palladium-catalyzed

fluorination mechanism recently published by Buchwald and co-workers.16 This method
has a tolerance of many functional groups which broadens the substrate scope to highly

19
complex targets. While the idea of a catalytic system seems attractive as a means to
fluorinate aromatic rings it is currently only practical for 19F incorporation. This process
requires high catalyst loading, and a long reaction time (12 h), which is not compatible
with 18F incorporation.

Figure 6.16 Metal catalyzed fluorination.
Electrophilic fluorination procedures have been used for the preparation of PET
radioligands.4 Electrophilic methods rely on the generation of

18

F-labeled F2. [18F2] is

produced via bombardment of gas containing neon and 0.1%

19

F2 with deuterons.

Scheme 1 shows the nuclear reaction used to produce electrophilic 18F, and application of
18

F2 in a fluorodemetalation reaction to produce [18F]FDOPA.17

20

Scheme 1. A. Process by which electrophilic 18F2 is produced. B. Incorporation of 18F2
into DOPA, used for PET imaging of brain dopamine metabolism.

There is an inherent problem associated with electrophilic fluorination: the
specific activity of the [18F]-fluorinated radioligands is always low. This problem arises
because of two reasons; one, the [18F]-labeled F2 only has one

18

F atom, thus the

maximum achievable radiochemical yield is only 50%3, and two, the concentration of gas
is 1,000-10,000 times that of the

18

F atom concentration. This dilution results in PET

ligands that are contaminated with huge amounts of the

19

F-labeled compound. The

presence of the nonradioactive PET ligand can degrade image quality and lead to
secondary drug effects and toxicity.
There has been a drive to develop no-carrier added fluorination reactions to avoid
the pitfalls of carrier-added fluorination. This has been achieved through the use of
nucleophilic radiofluroinations.3 The amount of radioactivity that can be produced in a
commercial cyclotron by proton bombardment of an

18

OH2 target is approximately 1000

GBq (~30 Cures). Specific activity is the amount of radioactivity per mole of compound.
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For per 18F-, the specific activity is on the order of 1 Curie (376 Bq) per 10 ng (~60
GBq/nanomole).
Direct introduction of no carrier-added fluoride is the reaction of choice for
preparing high specific activity material. Direct nucleophilic fluorination reactions are
severly limited in scope, generally the arene to be fluorinated must possess an electronwithdrawing group. The reaction must be carried out under extremely dry conditions.
The fluoride ion, 18F-, is a poor nucleophile in an aqueous environment. Fluoride can be
activated with the addition of a cryptand and tetra-n-butylammonium salt, in most cases
these are Kryptofix 2.2.2.(cryptand) and potassium carbonate (tetra-n-butylammonium
salt).

Nucleophilic radio-fluorinations of aliphatic systems usually follow a Sn2

mechanism in dipolar aprotic solvents. Classically, only activated (NO2, CN, CHO, and
COOR) aromatic rings were needed to incorporate the

18

F moiety, but not all clinically

relevant biomolecules contain an activating group, there is a drive to become creative
with the chemistry.
2.2 Using 18F as a labeling agent
The current technique for production of

18

F is proton bombardment of H2O18.

Following bombardment, the [18F]-fluoride is trapped on an ion exchange resin, and
eluted with aqueous carbonate or bicarbonate (Figure 6). Residual water is removed by
multiple azeotropic distillations with acetonitrile.

22

Figure 7. Method for isolation of 18F ion from cyclotron product.
The addition of Kriptofix 2.2.2 helps to solubilize the fluoride ion in polar aprotic
solvents, and sequesters the cation to bolster the fluoride ion nucleophilicity.
2.3 Diaryliodonium salts
Diaryliodonium salts, λ3diaryl-iodanes, were first synthesized in 1894.18 These
compounds are air and moisture stable, which make them attractive reagents in organic
synthesis. Scheme 3 shows two reactions that diaryliodonium salts are commonly used
in. Diaryliodonium salts can be formed as either symmetrical or unsymmetrical salts
(Scheme 3.a); this avoids any selectivity issues when reductive elimination occurs. The
nucleophilic displacement of the iodonium salt will reductively eliminate to the desired
ring. It is believed that the iodonium salts proceed through a reductive elimination
mechanism, in which the aryl-group is transferred to the nucleophile (Scheme 3.b).

23
Iodonium salts can act as aryl-iodides and transfer the aryl group and ligand to a metal; as
in an oxidative addition.18

Scheme 2.18 Some common uses for diaryliodonium salts. (a) General structure
for diaryliodonium salts, X = Cl, Br, I OTf, OTs. (b) Reaction of diaryliodonium
salts and nucleophiles. (c)Metal catalyzed reactions of diaryliodonium salts,
yielding cross coupling products.
Reductive elimination of diaryliodonium salts would seem to be a facile way to
introduce

18

F in an efficient and selective manner. In Scheme 4 it can be seen that this

method is reported to work on several systems with diverse functionality.
It has been shown that thermal decomposition of diaryliodides favor
functionalization on the electron-poor ring, while the iodine stays on the electron-rich
ring.18

The directing group in iodonium reactions can vary.

Scheme 4 shows the

directing group as a p-methoxy phenyl, but the directing group can be any aryl group,
most notably 2-thienyl and p-cyclophane.

24

Scheme 3. Some examples of radiofluroination with Diaryliodonium salts.1 RCY
is decay-corrected radiochemical yield.
2.4 Established protocol for mGluR5 synthesis

Scheme 4. Synthetic approach for radio-labeled PEB.13
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Hamill and coworkers (Merck Research Laboratories) were the first to synthesize
the mGluR5 ligand. Most chemical transformations used in PET radiotracer synthesis
take less than 20 minutes.

While the reaction time is suitable for PET radiotracer

synthesis, the yield was atrocious. This method left much ground to make up if this was
to be widely utilized as a synthetically useful reaction.
2.5 New Synthetic Approach for F-PEB
There is a need for a new method for nucleophilic fluorination, one that increases
yield and maintains the short reaction time. The DiMagno group has developed a method
for fluorination of electron deficient aromatic rings. This method utilizes hypervalent
iodine to introduce fluorine in relatively high yields (>70%). This newly developed
iodonium chemistry begins with a halogenated precursor.

Scheme

5.

The

preparation

of

3-bromo-5-((6-methylpyridin-2-

yl)ethynyl)benzonitrile
Reagents and conditions: (a) (trimethylsilyl) acetylene, PdCl2(PPH3)2, CuI, Et3N,
90 oC; (b) KOH, MeOH, room temp; (c) 3,5-dibromobenzonitrile, PdCl2(PPh3)2,
CuI, Et3N, 90 oC.
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The brominated precursor of PEB (1, Scheme 5) was synthesized in 2005 by the
Tamagnan group.15 The commercially available starting material, 2-bromopyridine, was
subjected to Sonogashira coupling with TMS-acetylene, using Pd (II). This first synthetic
step took about 12 hours at 90 oC and had a very high yield, 96%.

The 2-

(trimethylsilylethnynyl)pyridine (2) product was easily purified by silica gel flash
chromatrography and deprotected with KOH and MeOH, in essentially quantitative yield
(3). A second, more challenging Sonogashira coupling reaction was performed with the
deprotected alkyne and 3,5-dibromobenzonitrile.

The reaction produced the desired

brominated pyridinylethnylyl benzonitrile (4), but also a large amount of Glaser coupled
diyne, which was only removed with difficulty from the desired product. To overcome
this problem, the alkyne concentration was kept low in the presence of a gross excess of
the dibromobenzonitrile. The alkyne was added in small aliquots over the course of
several hours.

Palladium catalyzed stannylation (5) was performed on the brominated

benzonitrile precursor. An important aspect of the stannylation step that should be noted
was that the reaction worked best when excess (4 equiv.) of Bu3Sn2 was used to eliminate
cross coupling products

Scheme 7. Stannylation of 3-bromo-5-(pyridin-2-ylethynyl)benzonitrile.
.
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Scheme 8. Iodonium chemistry of PEB. Reagents and conditions: (a)TMS-TFA
acetonitrile;

(b) CH3CN, 40 oC, 14 hrs. (c) H2O, NaPF6; (d) Ion-exchange

column.
Preparation of the PEB derived diaryliodonium triflate is shown in Scheme 7.
The stannane condensed smoothly with 4-methoxyphenyliodonium diacetate upon
activation with trifluoroacetic acid (TFA). In this process, TFA replacing once acetate
group with a trifluoroacetate, making the I(III) center more electrophilic. Isolation of the
diaryliodonium salt was facilitated by the addition of aqueous NaPF6 to precipitate it
from water, and extraction with hexane to remove the various tributyl-impurities. Ionexchange (Amberlite-IRA 400 ion exchange resin) to the triflate was facile.

Scheme 9. Fluorination procedure for PEB. A. TMAF, CH3CN. B. Pumped off CH3CN,
dissolve in C6H6, filter and heat to 140 oC.

28

Our laboratory has optimized procedures for thermal decomposition of
diaryliodonium salts.19 It was found that the use of a low polarity, non-coordinating
solvents,

would improve yields of fluorinated arenes and suppresses noxious side

products arising from electron-transfer and disproportionation processes. Prior to this
work, the use of benzene as a solvent in PET radiotracer synthesis was unprecedented;
the typical solvents are polar aprotic (CH3CN, DMF). Also, our laboratory has shown
that the removal of electrolytes also improves yields significantly.

Inorganic salts

produced from ion exchange should not act in the thermal decomposition of
diaryliodonium salts, but they may act in ligand exchange and increase the I-F
dissociation rate and dissociation constant.19
To prepare the [19F]-fluorinated PEB derivatives the triflate salt was dissolved in
an acetonitrile solution of tertamethyl ammonium fluoride (TMAF). Exchange of triflate
and fluoride is instantaneous and verified by 19F NMR spectroscopy. To remove the inert
electrolyte (TMA-OTf), the acetonitrile was evaporated and the remainder was dissolved,
to the extent possible, in dry d6-benzene. This solution was passed through a 0.20 um
PTFE syringe filter. Reductive elimination of F-PEB was achieved simply by heating the
benzene solution at 140 oC (sealed tube) for 20 minutes. Fluorination was very selective,
no fluoroanisole was formed. The F-PEB was separated from 4-iodoanisole by using a
column chromatography (silica gel, ethyl acetate : hexane, 85:15) (70%).
There has been research attention placed on mGluR5 radiotracers that contain a
methyl group adjacent to a nitrogen atom in one of the rings.15 PEB was taken as a

29
template, and methyl-Pyridinylethynyl Benzonitrile was investigated as a potential target
for this project. As expected the synthetic strategy was high yielding, 60% fluorinated
drug; and highly selective, no fluoroanisole formation.

Scheme 10. Synthetic strategy for M-PEB.
The fore mentioned synthesis was performed on methyl-Pyridinylethynyl
Benzonitrile, MPEB.

All reagents and conditions were exactly the same; detailed

characterization can be found in the experimental section.
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CHAPTER THREE
3.1 Expansion of Methodology to Aromatic Amino Acids
Glucose (2FDG) has been used in PET imaging to show tumor location. Tumors
show an increase of glucose uptake and metabolism, this may is due to the higher energy
demands of a rapidly proliferating cell and over expression of glucose transporters. A
drawback to using glucose as a PET tracer is that it is not specific, and it would also show
up in areas of normal high glucose usage, i.e. the brain and the heart.

Many

amino

acids have been investigated as radiotracers to solve the high background response in
2FDG. R. M. Johnstone in 1965 showed that amino acid transport and protein synthesis
is increased in tumor cells.20 Amino acids can be used as radiotracers, and can be used to
visualize amino acid accumulation in tumor tissue; in some cases the amino acid tracers
are actually incorporated into growing protein inside tumor cells. Advantages of using
amino acids as radiotracers is that they have a higher specificity for particular cancer
cells, especially in the brain, and are less likely to give rise to high background signals, as
is the case for 2-FDG.21

Figure 7 shows two very recent fluorinated amino acid

radiotracers used in PET imaging.
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Figure 8. Current amino acid analogues used for PET imaging. FET,
[18F]fluoroethyl tyrosine; BAY 85-8050, 4-[18F]Fluoroglutamic Acid.
[18F]fluoroethyl tyrosine, [18F]FET, is currently under investigation for targeting tumor
cells in the brain.22 [18]FET has one major drawback due to the radiotracer being trapped
in peripheral tissue, giving rise to a large background signal. To overcome this challenge
BAY 85-8050 was developed.

23

This

18

F glutamate derivative has been shown to be

taken up selectively in lung and colon cancer cell lines.23

These initial results

demonstrates the potential for 18F labeled amino acid radiotracers to be used in oncology
imaging.
Although few examples of

18

F-labled amino acids as PET imagers are known,

Figure 8 shows the variety of aromatic amino acids that can be 18F radio labeled with the
techniques developed in the DiMagno laboratory. [18F]-labeled aromatic amino acids
present significant challenges for their synthesis with n.c.a. fluoride; protection schemes
need to be developed that are compatible with I(III) salt formation and nucleophilic
fluorination.

Figure 9. Possible aromatic amino acid radio tracers. Red X implies position of
18

F isotope. A. phenylalanine, b. tyrosine, c. tryptophan, d. histidine.
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In our approach the position ultimately bearing the

18

F-label must be able to be

halogenated selectively, and from the halogenated precursor the iodonium chemistry
would be identical to the procedure described in Chapter 2.
There is a need to have a high yielding fluorination technique in [18F]-PET. The
new method described here, which utilizes iodonium salts, is not only high yielding, but
also fits in with the short half-life and fast synthesis that is required for
This opens the door for usage of 18F labeled drugs in PET imaging.

18

F chemistry.

33
REFERENCES
1. Cai, L.; Lu, S.; Pike, V. W. European Journal of Organic Chemistry 2008, 28582873.
2. Miller, P. W.; Long, N. J.; Vilar, R.; Gee, A. D. Angew. Chem. Int. Ed 2008, 47,
8998-9033.
3. Holland, J. P.; Williamson, M. J.; Lewis, J. S. Molecular Imaging 2010, 9(1) 1-20.
4. DiMagno, S. G.; Sun, H.; Current Topics in Medical Chemistry 2006, 6, 14731482.
5. Global Industry Analyst “Radiopharmaceuticals – A US and European Market
Report”
6. Kew, J. N. C.; Kemp, J. A. Psychpharmacology 2005, 179, 4-29.
7. Nelson, D. L.; Cox, M. M. 2005. Lehninger: Principles of Biochemistry 4th Ed.
New York. W. H. Freeman and Company.
8. Pin, J.P.; Duvoisin, R. Neuropharmacology 1995, 34(1) 1-26.
9. Gasparini, F.; Bilbe, G.; Gomez-Mancilla, B.; Spooren, W. Current Opinion in
Drug Discovery & Development 2008, 11(5), 655-665. Belanger, M.; Krause, S.
M.; Ryan, C.; Sanabria-Bohorquez, S.; Li, W.; Hamill, T.G.; Burns, H. D.
Nuclear Medicine Communications 2008, 29, 915-919.
10. Wang, J.; Brownell, A. Current Medical Imaging Reviews 2007, 3, 186-205.
11. Schoepp, D. D.; Goldsworthy, J.;Johnson, B. G.;Salhoff, C.R.; Baker, S. R.;
Journal of Neurochemistry 1994, 63(2), 769-772.
12. Varney, M.A; Cosford, N.D.P.; Jachec, C.; Rao, S. P.; Sacaan, A.; Lin, F.;
Bleicher, L.; Santori, E. M.; Flor, P.J.; Allgeier, H.; Gasparini, F.; Kuhn, R.; Hess,

34
S.D.; Velicelebi, G.; Johnson, E.C. Journal of Pharmacology and Experimental
Therapeutics 1999, 290(1), 170-181.
13. Hamill, Terence G.; Krause, Stephen; Ryan, Christine; Bonnefous, Celine;
Govek, Steve; Seiders, T. Jon; Cosford, Nicholas D. P.; Roppe, Jeffrey;
Kamenecka, Ted; Patel, Shil Synapse 2005, 56(4), 205-216.
14. Patel, S.; Hamill, T.G.; Connolly, B.; Jagoda, E.; Li, W.; Gibson, R.E. Nuclear
Medicine and Biology 2007, 34, 1009-1017.
15. Alagille, D.; Baldwin, R. M.; Roth, B.L.; Wroblewski, J.T.; Grajkowska, E.;
Tamagnan, G.D. Bioorganic & Medicinal Chemistry 2005 , 13, 197-209.
16. Watson, D.A.; Su, M.; Teverovskiy, G.; Zhang, Y.; Garcia-Fortanet, J.; Kinzel,
T.; Buchwald, S.L. Science 2009, 325, 1661-1664.
17. Namavari, M.; Bishop, A.; Satyamurthy, N.; Bida, G.; Barrio, J.R. Applied
Radiation and Isotopes 1992, 43(8), 989-996.
18. Merritt, E.A.; Olofsson, B. Angew. Chem. Int. Ed. 2009, 48, 9052-9070.
19. Wang, B.; Qin, L.; Neumann, K.D.; Uppaluri, S.; Cerny, R.L.; DiMagno, S.G.
Organic Letters 2010, 12(15), 3352-3355.
20. Johnstone, R.M.; Scholefield, P.G. Adv. Cancer Res. 1965, 9, 143-226.
21. Kubota, K.; Yamada,K.; Yoshioka, S.; Ito, M.; Ido, T. Clinical Nuclear Medicine
1992, 17, 361-363.
22. Hess, E.; Sichler, S.; Kluge, A.; Coenen, H.H. Applied Radiation and Isotopes
2002, 57(2), 185-191.
23. Krasikova, R.N.; Kuznetsova, O.F.; Fedorova, O.S; Belokon, Y.N.; Maleev, V.I.
Mu, L.; Ametamev, S.; Schubiger, P.A.; Friebe, M.; Berndt, M.; Koglin, N.;

35
Mueller, A.; Graham, K.; Lehmann, L.; Dinkelborg, L.M. Journal of Medicinal
Chemistry 2011, 54, 406-410.

36
EXPERIMENTAL PROCEDURES

2-((trimethylsilyl)ethynyl)pyridine
Ref: Bioorg. Med. Chem. Let. 16 (2006) 4788-4791
Into a 50 mL schlenk tube was placed triethylamine (15 mL), 2-bromopyridine (2.0g,
12.66 mmol), and trimethylsilylacetylene (1.65 mL, 15.12 mmol). The reaction mixture
was freeze, pumped, thawed three times. The reaction mixture was transferred to a small
storage tube charged with Pd(PPh3)2Cl2 (0.145g, 5 mol %), CuI (0.0049 g, 5 mol %), and
a flea stir bar. The solution was capped and heated to 90 oC for 12 hrs. Once the reaction
was completed the storage tube was cooled to room temperature and contents run through
a silica plug with ethyl acetate, to remove the catalyst. The elutant was concentrated via
rotary evaporation. The concentrate was purified by flash chromatography (silica gel, 95
: 5 hexanes : ethyl acetate elutant). The solvent was removed in vacuo leaving the
product as a brown oil. (2.1 g, 95%)
1

H NMR (400 MHz, CDCl3):  = 8.5 (dd, 1 H, J1 = 0.4 Hz, J2 = 4.8 Hz), 7.71 (dt, 1 H, J1

= 1.6 Hz, J2 = 7.8 Hz), 7.4 (td, 1 H, J1 = 0.8 Hz, J2 = 7.8 Hz), 7.3 (ddd, 1 H, J1 = 4.8, J2 =
3.6, J3 = 7.8), 0.25 (s, 3 H).

13

C NMR (100 MHz, CD3CN):  = 151.1, 143.63, 137.46,

128.29, 124.47, 118.29, 105.12, 94.72, -0.25.
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2-((trimethylsilyl)ethynyl)pyridine
In a 100 mL round bottom flask was placed methanol (20 mL), KOH (0.18g, 3.2 mmol),
and 2 trimethylsilylethynyl pyridine (300 mg, 1.7 mmol). Solution was allowed to stir at
room temperature for 2 hrs. The solvent was removed in vacuo. Concentrate was
combined with 10 mL of water. Product was extracted with three washes of ethyl
acetate. Product was dried over sodium sulfate and solvent was removed via rotary
evaporation yielding a light yellow oil. No further purification was necessary. ( 0.176g,
100 %)
1

H NMR (400 MHz, CDCl3): = 8.55(d, 1 H, J = 4.8 Hz), 7.62 (dt, 1 H, J1 = 6.4 Hz, J2 =

1.6 Hz), 7.44 (d, 1 H, J = 8Hz), 7.22 (t, 1 H, J = 5.6 Hz), 3.13 (s, 1 H).

13

C NMR (100

MHz, CDCl3) :  = 150.02, 142.32, 136.16, 127.45, 123.41, 82.73, 77.14.

3-bromo-5-(pyridin-2-ylethynyl)benzonitrile
Into a schlenk tube was placed dibromobenzonitrile (4.0 g, 15.7 mmol), 2-ethynyl
pyridine (1.84 g, 15.7 mmol), and triethylamine (~50 mL).

Reaction mixture was
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degassed by freeze, pump, thawing three times. Solution was transferred to a storage
tube containing Pd(PPh3)2Cl2 (0.375 g, 3 mol %), and a catalytic amount of CuI. Storage
tube was capped and heated to 90 oC for 18 hrs. Once the reaction was completed the
storage tube was cooled to room temperature and contents run through a silica plug with
ethyl acetate, to remove the catalyst.

The solvent was concentrated via rotary

evaporation. The concentrate was purified by flash chromatography (silica gel, 80 : 20
hexanes : ethyl acetate). The solvent was removed in vacuo leaving the product was an
off white solid (1.99, 45 %).
1

H NMR (400 MHz, CDCl3):  = 8.6 (dd, 1 H, J1 = 1.4 Hz, J2 = 2.8 Hz), 7.9 (t, 1 H, J =

1.6 Hz), 7.8 (dt, 1 H, J1 = 1.6 Hz, J2 = 7.6), 7.7 (td, 1 H, J1 = 1.6 Hz, J2 = 7.6 Hz), 7.5 (d,
1 H, J = 8 Hz), 7.3 (ddd, 1 H, J1 = 1.2 Hz, J2 = 3.6 Hz, J3 = 7.6 Hz).

13

C NMR (100 MHz,

CDCl3):  = 150.36, 142.08, 138.83, 136.41, 134.62, 133.71, 127.54, 125.61, 123.74,
122.85, 116.54, 114.42. 91.95, 84.80.

3-(Pyridin-2-ylethynyl)-5-(tributylstannyl)benzonitrile
3-Bromo-5-(pyridin-2-ylethynyl) benzonitrile (0.500g, 1.77 mmol) was dissolved in a
minimal amount of benzene and transferred to a heavy-walled glass storage tube
equipped with a threaded PTFE closure. Hexabutylditin (3.07g, 5.30 mmol), and benzene
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(10 mL) were added. Bis(tri-tert-butylphosphine)palladium was prepared as follows:
Pd(dba)2 (80.8 mg, 0.0883 mmol) and P(t-Bu)3 (44.6 mg, 0.221 mmol) were dissolved
separately in benzene and combined. The catalyst mixture was allowed to stir until the
solution changed from deep purple to dark red, and the solution was passed through a 0.2
m membrane filter and added directly to the storage tube. The reaction flask was
sealed, protected from light by shielding with aluminum foil, and the solution was heated
at 110 °C for 3 days. The solution was cooled, the benzene was removed in vacuo, and
the crude product was purified by flash chromatography (silica gel, 93:7
hexanes:triethylamine eluant). The solvent was removed in vacuo leaving the product as
a viscous yellow oil (0.350g, 40%).
1

H NMR (300 MHz, CD3CN):  = 8.4 (d, 1 H, J = 4.2 Hz), 7.87 (s, 1 H), 7.56 (s, 1 H),

7.29 (d, 1 H, J = 1.8 Hz), 7.20 (s, 1 H), 6.88 (dt, 1 H, J 1 = 2.0 Hz, J2 = 1.9 Hz), 6.50 (dd,
1 H, J1 = 5.0 Hz, J2 = 7.8 Hz), 1.542 (t, 1 H, J = 8.0 Hz), 1.31 (q, 6 H, J = 16 Hz), 1.15
(h, 6 H, J = 8.2 Hz), 0.884 (t, 9 H, J = 7.2 Hz). 13C NMR (75 MHz, CD3CN):  = 150.4,
142.8, 139.0, 135.4, 129.9, 127.7, 127.0, 123.4, 122.7, 118.3, 113.2, 29.0, 27.3, 13.6, 9.6.
HR-FAB MS: (M+H)+ = 495.1831 m/z (calcd for C26H34N2Sn, 494.174)
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(3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium
hexafluorophosphate
3-(Pyridin-2-ylethynyl)-5-(tributylstannyl)benzonitrile (25.0 mg, 0.0500 mmol), 4methoxyphenyliodonium

diacetate

(35.8mg,

0.0999

mmol),

and

trimethylsilyl

trifluoroacetate (20.5mg, 0.110 mmol) were combined in CD3CN and placed in a J.
Young NMR tube. The reaction mixture was heated at 40 °C for 11 h, and its progress
was monitored by 1H NMR spectroscopy. Upon completion of the reaction, water (4.5
mL) was added to precipitate tributyltin acetate and the solution was filtered. Sodium
hexafluorophosphate (25.19 mg, 0.150 mmol) was added to the filtrate and the
precipitated

(3-cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium

hexafluorophosphate was collected by membrane filtration. The solid was redissolved in
CH2Cl2 to remove it from the filter and the solvent was evaporated. The colorless solid
was recrystallized from CH2Cl2/heptanes to give a colorless, crystalline solid. (14.6 mg,
50%).
1

H NMR (300 MHz, CD3CN)  = 8.63 (d, 1 H, J = 4.8 Hz), 8.49 (d, 1 H, J = 1.2 Hz),

8.40 (s, 1 H), 8.21 (d, 1 H , J = 0.8 Hz), 8.01 (d, 2 H, J = 9.2 Hz), 7.90 (t, 1 H, J = 7.6
Hz), 7.68 (d, 1 H, J = 7.6 Hz), 7.48 (t, 1 H, J = 6.2 Hz), 7.10 (d, 2 H, J = 9.2 Hz), 3.86 (s,
3 H); 13C NMR (75 MHz, CD3CN) d = 150.51, 141.36, 139.12, 138.22, 137.92, 136.81,
127.89, 124.35, 118.44, 117.30, 115.64, 55.84; 19F NMR (282 MHz, CD3CN): -72.96 (d,
6 F, J = 705 Hz); HR-FAB MS: (M-PF6)+ 437.0149 m/z (calcd for C21H14IN2O,
437.0145)

41

OTf
N

I

CN

OMe

(3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium
trifluoromethanesulfonate
(3-cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium
hexafluorophosphate (52mg, 0.0894 mmol) was dissolved in a minimal amount (0.5mL)
of acetonitrile. The solution was passed through a 12 mm diameter column packed to a
height of 10 cm with Amberlite-IRA 400 ion exchange resin (OTf) in acetonitrile.
Evaporation of the eluted product yielded a colorless solid that was recrystallized from
acetone/hexane

to

yield

(3-cyano-5-(pyridine-2-ylethynyl)phenyl)(4-

methoxyphenyl)iodonium trifluoromethanesulfonate (52.0 mg, 100%)
1

H NMR (300 MHz, CD3CN)  8.64 (d, 1 H, J = 7.0 Hz), 8.47 (s, 1 H), 8.39 (s, 1 H),

8.20 (s, 1 H), 8.06 (d, 2 H, J = 9.3 Hz), 7.82 (d, 1 H, J = 7.5 Hz), 7.63 (d, 1 H, J = 8.4
Hz), 7.40 (d, 1 H, J = 7.0 Hz), 7.09 (d, 2 H, J = 9.0 Hz), 3.86 (s, 3 H);

13

C NMR (75

MHz, CD3CN): 163.79, 159.71, 141.49, 139.30, 138.29, 138.22, 118.46, 116.54, 113.15,
81.87, 55.85, 55.04;

19

F NMR (282 MHz, CD3CN): -79.35 (s); HR-FAB MS: (M-OTf)+

437.0156 m/z (calcd for C21H14IN2O, 437.0145)
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3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile
(3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium
trifluoromethanesulfonate (25 mg, 0.0427 mmol) and TMAF (3.3mg, 0.0417 mmol) were
combined in CH3CN to effect ion exchange. The solvent was removed in vacuo, the
residue was treated with C6D6 (0.8 mL) and the solution was passed through a membrane
filter (0.2 m pore size) directly into an NMR tube that was equipped with a PTFE valve.
The reaction mixture was heated at 140 ºC for 15 minutes. Product was purified by flash
chromatography (silica gel, 85:15 hexanes:ethyl acetate eluant).

The solvent was

removed in vacuo leaving the product as a crystalline white powder (7 mg, 70%)
19

F NMR (376 MHz, CD3CN): -111.81 ( t)

Preparation

of

an

analytical

standard

of

3-Fluoro-5-(pyridine-2-

ylethynyl)benzonitrile
A sample of 3-fluoro-5-(pyridine-2-ylethynyl)benzonitrile was performed by standard
methods to provide an analytical HPLC standard. 2-Ethynylpyridine (100 mg, 0.971
mmol) and 2-bromo-4-fluorobenzonitile (192 mg, 0.965 mmol) were dissolved separately
in trimethylamine (5 mL) and placed into a heavy-walled glass storage tube equipped
with a threaded PTFE closure. The reaction mixture was degassed and transferred by
cannula into a separate heavy-walled glass storage tube fitted with a threaded PTFE
closure containing bis(triphenylphosphine)palladium dichloride (34 mg, 5 mol %) and
CuI (4.3 mg, 5 mol %). The reaction was capped and heated to 80 °C for 18 h. The
cooled solution was extracted from water using ethyl acetate, and the organic layer was
dried over sodium sulfate. Flash chromatography (silica gel, 95:5 hexanes:ethyl acetate
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eluant) and evaporation of the solvent provided the product as a light yellow solid.
Recrystallization was performed with hexanes to yield colorless crystals. (64.7 mg, 30 %)
1

H NMR (400 MHz, CD3CN): 8.62 (dd, 1 H, J1 = 0.8 Hz, J2 = 3.4 Hz), 7.81 (dt, 2 H,

J1=2.0 Hz, J2= 7.8 Hz), 7.66 (ddd, 1 H, J1 = 1.6 Hz, J2 = 2.6 Hz, J3 = 9.2 Hz), 7.62 (td, 1
H, J1 = 0.8 Hz, J2 = 8.0 Hz), 7.59 (ddd, 1 H, J1 = 1.2 Hz, J2 = 2.4 Hz, J3 = 8.4 Hz), 7.39
(ddd, 1 H, J1 = 0.8 Hz, J2 = 5.0 Hz, J3 = 8.0 Hz);

13

C NMR (75 MHz, CD3CN):

168.87, 165.58, 155.70, 147.25, 141.99, 137.15, 137.10, 133.96, 130.96, 130.82,
129.29, 128.83, 128.52, 125.43, 125.10, 119.65, 119.51, 96.57;

19

F NMR (376 MHz,

CD3CN): -111.81 ( t, 1 F); HR-FAB MS: (M+H)+ = 223.0674 (calcd for C14H7FN2,
222.06)

2-methyl-6-((trimethylsilyl)ethynyl)pyridine
Into a 50 mL schlenk tube was placed triethylamine (30 mL), 2-bromo-6-methylpyridine
(2.0g, 11.63 mmol), and trimethylsilylacetylene (1.36 mL, 13.95 mmol). The reaction
mixture was freeze, pumped, thawed three times. The reaction mixture was transferred to
a small storage tube charged with Pd(PPh3)2Cl2 (0.163 g, 2 mol %), CuI (0.044 g, 2 mol
%), and a flea stir bar. The solution was capped and heated to 90 oC for 12 hrs. Once the
reaction was completed the storage tube was cooled to room temperature and contents
run through a silica plug with ethyl acetate, to remove the catalyst. The elutant was
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concentrated via rotary evaporation.

The concentrate was purified by flash

chromatography (silica gel, 95 : 5 hexanes : ethyl acetate elutant). The solvent was
removed in vacuo leaving the product as a brown oil. (2.09 g, 95 %)
1

H NMR (400 MHz, CDCl3): = 7.5 (t, 1 H, J1 = 7.6 Hz), 7.2 (d, 1 H, 7.6 Hz), 7.0 (d, 1

H, 7.6 Hz), 2.5 (s, 3 H), 0.2 (s, 9 H).

13

C NMR (100 MHz, CDCl3):  = 158.84, 142.31,

136.25, 124.57, 122.85, 103.88, 94.16, 24.57, -0.24.

2-methyl-6-((trimethylsilyl)ethynyl)pyridine
In a 100 mL round bottom flask was placed methanol (33 mL), KOH (1.29g, 23.0 mmol),
and 2 trimethylsilylethynyl pyridine (2.09 g, 17.9 mmol). Solution was allowed to stir at
room temperature for 2 hrs. The solvent was removed in vacuo. Concentrate was
combined with 10 mL of water. Product was extracted with three washes of ethyl
acetate. Product was dried over sodium sulfate and solvent was removed via rotary
evaporation yielding a light yellow oil. No further purification as necessary. ( 1.19g, 92
%).
1

H NMR (300 MHz, CDCl3):  = 7.56 (t, 1 H, J = 7.8 Hz), 7.32 (d, 1 H, J = 7.5), 7.15 (d,

1 H, J = 7.8), 3.14 (s, 1 H), 2.57 (s, 3 H).
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3-bromo-5-((6-methylpyridin-2-yl)ethynyl)benzonitrile
Into a schlenk tube was placed dibromobenzonitrile (3.15g,12.2 mmol), 2-ethynyl-6methyl pyridine (1.19g, 10.17 mmol), and triethylamine (~50 mL). Reaction mixture was
degassed by freeze, pump, thawing three times. Solution was transferred to a storage
tube containing Pd(PPh3)2Cl2 (3 mol %), and a catalytic amount of CuI. Storage tube was
capped and heated to 90 C for 18 hrs. Once the reaction was completed the storage tube
was cooled to room temperature and contents run through a silica plug with ethyl acetate,
to remove the catalyst.

The solvent was concentrated via rotary evaporation. The

concentrate was purified by flash chromatography (silica gel, 85 : 15 hexanes : ethyl
acetate). The solvent was removed in vacuo leaving the product was an off white solid
(1.78g, 59%).
1

H NMR (400 MHz, CDCl3):  = 7.66 (s, 1 H), 7.6 (t, 1 H, J = 8 Hz), 7.5 (dq, 1 H, J 1 =

8.8 Hz, J2 = 1.6 Hz), 7.36 (d, 1 H, J = 8 Hz), 7.35 (dq, 1 H, J1 = 12 Hz, J2 = 1.2 Hz), 7.1
(d, 1 H, J = 7.6 Hz), 2.6 (s, 3 H).

13

C NMR (100 MHz, CDCl3):  = 163.08, 160.59,

159.29, 141.28, 136.56, 131.39, 126.22, 124.83, 123.35, 119.38, 116.79, 114.39, 92.03,
84.54, 24.66.
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3-((6-methylpyridin-2-yl)ethynyl)-5-(tributylstannyl)benzonitrile
3-bromo-5-((methylpyridin-2-yl) ethynyl) benzonitrile (1g, 1.97 mmol) was dissolved in
a minimal amount of benzene and transferred to a heavy walled glass storage tube
equipped with a threaded PTFE closure.

Hexabutylditin (3.44g, 5.90 mmol), and

benzene (10ml) were added. Bis(tri-tert-butylphosphine) palladium was prepared as
follows: Pd(dba)2 (0.126 mg, 0.138 mmol) and P(t-Bu)3 (69.8 mg, 0.345 mmol) were
dissolved separately in benzene and combined. The catalyst mixture was allowed to stir
until the solution changed from a deep purple to a dark red. The catalyst mixture was
passed through a 0.2 um membrane filter and directly to the storage tube. The reaction
flask was sealed, protected from light by shielding with aluminum foil, and the solution
was heated to 110 o C for 3 days. The solution was cooled, the benzene was removed in
vacuo, and the crude product was purified by flash chromatography (silica gel, 90:10
hexanes:triethylamine eluant). The solvent was removed in vacuo leaving the product as
a viscous yellow oil (0.460 g, 46%).
1

H NMR (400MHz, CD3CN):  = 7.93 (d, 1 H, J = 0.8 Hz), 7.84 (s, 1 H), 7.83 (s, 1 H),

7.67 (t, 1 H, J = 7.8 Hz), 7.41 (d, 1 H, J = 7.6 Hz), 7.24 (d, 1 H, J = 8.0 Hz), 2.51 (s, 3 H),
1.52 (q, 6 H, J = 8.6 Hz), 1.39 (s, 6 H, J = 6.9 Hz), 1.15 (t, 6 H, J = 7.8 Hz), 0.88 (t, 9 H,
J = 7.35 Hz); 13C NMR (75 MHz, CD3CN):  = 159.30, 145.21, 143.31, 141.62, 139.69,
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136.82, 134.44, 124.57, 123.22, 122.66, 118.18, 112.18, 90.53, 85.90, 28.66, 26.95,
23.52, 12.92, 9.47; HR-FAB MS: (M+H)+ = 509.1979 (calcd for C27H36N2Sn, 508.19)

(3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-methoxyphenyl)iodonium
hexafluorophosphate
3-(pyridin-2-ylethynyl-6-methyl)-5-(tributylstannyl)benzonitrile (25.0 mg, 0.0420 mmol),
diacetateiodoanisole (29.5mg, 0.0838 mmol), and trimethylsilyl-trifluroacetate (11.7 mg,
0.0630 mmol) were combined in CD3CN and placed in J. Young NMR tube. The
reaction mixture was heated to 40 °C for 12 hrs, the reaction was monitored by 1H NMR
spectroscopy. Upon completion of the reaction, the reaction mixture was combined with
water (4.5g, 0.250 mol) to precipitate the tributyltin-acetate and the solution was filtered.
The filtrate was combined with Sodiumhexaflurophosphate (25.19 mg, 0.150 mmol) and
the

precipitated

(3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-

methoxyphenyl)iodonium hexafluorophosphate was collected by membrane filtration.
The solid was redissloved in CH2Cl2 to remove it from the filter and the solvent
evaporated. The colorless solid was recrystallized from CH2Cl2/heptanes to give a
colorless, crystalline solid (12.5mg, 50%).
1

H NMR (400MHz, CD3CN):  = 8.47 (s, 1 H ), 8.39 (s, 1 H), 8.20 (s, 1 H), 8.07 (d, 2 H,

J = 8.1 Hz), 7.72 (t, 1 H, J = 8.0 Hz), 7.44 (d, 1 H, J = 8.0 Hz), 7.29 (d, 1 H, J = 8.0 Hz),
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7.10 (d, 2 H, J = 9.2 Hz), 3.86 (s, 3 H), 2.52 (s, 3 H). 13C NMR (100 MHz, CD3CN):  =
163.82, 159.59, 141.36, 140.57, 139.16, 138.29, 137.89, 137.10, 126.78, 125.09, 124.06,
118.49, 115.66, 112.93, 101.28, 93.33, 82.99, 55.85, 23.46; 19F (376 MHz, CD3CN)  = 72.79 (d, 6 F, 703.1 Hz); HR-FAB MS: (M-PF6)+ 451.0299 m/z (calcd for C22H16IN2O,
451.03)

(3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-methoxyphenyl)iodonium
trifluoromethanesulfonate
(3-cyano-5-(pyridine-2-ylethynyl-6-methyl)phenyl)(4-methoxyphenyl)iodonium
hexafluorophosphate (50 mg, 0.0839 mmol) was dissolved in a minimal amount(0.5 mL)
of acetonitrile. The solution was flowed through a 12 mm diameter column packed to a
height of 10 cm with Amberlite-IRA 400 ion exchange resin (OTf) in acetonitrile.
Evaporation of the eluted product yielded a colorless solid that was recrystallized from
acetone/hexane

to

yield

(3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-

methoxyphenyl)iodonium trifluoromethanesulfonate ( 50 mg, 100%).
1

H NMR (400MHz, CD3CN):  = 8.47 (t, 1 H, J = 1.2 Hz), 8.39 (t, 1 H, J = 1.6 Hz), 8.18

(d, 1 H J = 1.2 Hz), 8.07 (dd, 2 H, J1 = 2.4 Hz, J2 = 7.2 Hz), 7.70 (t, 1 H, J = 7.8 Hz),
7.44 (d, 1 H, J = 7.6 Hz), 7.29 (d, 1 H, J = 7.6 Hz), 7.09 (dd, 2 H, J1 = 2.0 Hz, J2 = 7.2
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Hz), 3.82 (s, 3 H), 2.51 (s, 3 H);

13

C (75 MHz, CD3CN):  = 163.70, 159.60, 141.36,

139.00, 138.24, 137.87, 136.97, 126.70, 125.04, 123.97, 118.38, 115.54, 113.28, 101.66,
55.82, 23.50, 23.50, 0.72;

19

F NMR (282 MHz, CD3CN):  = -79.30 (s, 3 F); HR-FAB

MS: (M-OTf)+ 451.0288 m/z (calcd for C22H16IN2O, 451.03).

Preparation of an analytical standard of 3- Fluoro-5-(6-methylpyridine-2ylethynyl)benzonitrile
Preparation of fluorinated standard was done for HPLC analysis.

6-methyl-2-

ethynylpyridine (100mg, 0.855 mmol) was placed in a storage tube along with 2-bromo4-fluorobenzonitile (171 mg, 0.855 mmol) and triethylamine (5 mL). The reactions
mixture was degassed and canulated into a storage tube containing Dichloroditriphenylphosphine palladium (II) ( 5 mol%) and CuI ( 5 mol%). The reaction was
capped and heated to 80 °C for 18 hrs. The reaction mixed was removed from heat and
an aqueous workup was performed with water and EtOAc. The organic layer was dried
over sodium sulfate. Flash chromatography was performed on the reaction mixture,
product eluted in 5% triethylamine in hexanes.

Product was brown solid.

Recrystalization was performed with hexanes to yield white crystals. (30%)
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1

H(400MHz, CD3CN): = 7.82 (s, 1 H), 7.72 (t, 1 H, J = 7.6 Hz), 7.67 (dd, 1 H, J1 = 1.0

Hz, J2 = 8.2 Hz,), 7.61 (dd, 1 H, J1 = 1.6 Hz, J2 = 8.2 Hz), 7.46 (d, 1 H, J = 7.6 Hz), 7.29
(d, 1 H, J = 8 Hz), 2.54 (s, 3 H);

13

C (75 MHz, CD3CN):  = 163.56, 160.23, 159.36,

141.24, 136.70, 131.51, 131.47, 126.25, 124.79, 123.65, 123.34, 119.56, 119.23, 116.78,
114.23;

19

F (376MHz, CD3CN):  = -112.18 (t, 7.52, 1 F); HR-FAB MS: (M+H)+

237.0825 m/z (calcd C15H10N2F, 236.07)

3-fluoro-5-(pyridine-2-ylethynyl-6-methyl)benzonitrile
Triflate precursor (25mg, 0.0427 mmol) was combined with TMAF (3.3mg, 0.0417
mmol) in acetonitrile-d3. This solution is to be kept fairly concentrated, entire process is
to be kept air-free. Exchange is instantaneous, and acetonitrile is pumped off. The
reaction is redissolved in benzene-d6, and filtered with a membrane filter. The reaction
mixture is heated to 140

o

C for 15 minutes.

Product was purified by flash

chromatography (silica gel, 85:15 hexanes:ethyl acetate eluant).

The solvent was

removed in vacuo leaving the product as a crystalline white powder (5.9 mg, 60%).
19

F (376MHz, CD3CN):  = -112.18 (t, 1 F)
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APPENDIX A.
Common Abbreviations Used in this Thesis
PET

Positron Emission Tomography

mGluR

metabotropic glutamate receptor

K. 2.2.2

Krytofix 2.2.2.

RCY

decay-corrected radiochemical yield

PEB

3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile

CH3CN

acetonitrile

C6H6

benzene

TMAF

Tetramethyl ammonium fluoride

MPEB

3- Fluoro-5-(6-methylpyridine-2-ylethynyl)benzonitrile
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APPENDIX B
NMR Spectra
1.

1

2.

13

3.

1

4.

13

5.

1

6.

13

7.

1

8.

13

9.

1

H of 2-((trimethylsilyl)ethynyl)pyridine in CDCl3
C of 2-((trimethylsilyl)ethynyl)pyridine in CDCl3

H of 2-((trimethylsilyl)ethynyl)pyridine in CDCl3
C of 2-((trimethylsilyl)ethynyl)pyridine in CDCl3

H of 3-bromo-5-(pyridin-2-ylethynyl)benzonitrile in CDCl3
C of 3-bromo-5-(pyridin-2-ylethynyl)benzonitrile in CDCl3

H of 3-(Pyridin-2-ylethynyl)-5-(tributylstannyl)benzonitrile in CD3CN
C of 3-(Pyridin-2-ylethynyl)-5-(tributylstannyl)benzonitrile in CD3CN

H of (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium

hexafluorophosphate in CD3CN
10. 13C of (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium
hexafluorophosphate in CD3CN
11. 19F of (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium
hexafluorophosphate in CD3CN
12. 1H of (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium
trifluoromethanesulfonate in CD3CN
13. 13C of (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium
trifluoromethanesulfonate in CD3CN
14. 19F (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium
trifluoromethanesulfonate in CD3CN
15. 19F of 3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile in CD3CN
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16. 1H of 3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile in CD3CN
17. 13C of 3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile in CD3CN
18. 19F of 3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile in CD3CN
19. 1H of 2-methyl-6-((trimethylsilyl)ethynyl)pyridine in CDCl3
20. 13C of 2-methyl-6-((trimethylsilyl)ethynyl)pyridine in CDCl3
21. 1H of 2-methyl-6-((trimethylsilyl)ethynyl)pyridine in CDCl3
22. 1H of 3-bromo-5-((6-methylpyridin-2-yl)ethynyl)benzonitrile in CDCl3
23. 13C of 3-bromo-5-((6-methylpyridin-2-yl)ethynyl)benzonitrile in CDCl3
24. 1H of 3-((6-methylpyridin-2-yl)ethynyl)-5-(tributylstannyl)benzonitrile in CD3CN
25. 13C of 3-((6-methylpyridin-2-yl)ethynyl)-5-(tributylstannyl)benzonitrile in
CD3CN
26. 1H of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4methoxyphenyl)iodonium hexafluorophosphate in CD3CN
27. 13C of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4methoxyphenyl)iodonium hexafluorophosphate in CD3CN
28. 19F of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4methoxyphenyl)iodonium hexafluorophosphate in CD3CN
29. 1H of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4methoxyphenyl)iodonium trifluoromethanesulfonate in CD3CN
30. 13C of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4methoxyphenyl)iodonium trifluoromethanesulfonate in CD3CN
31. 19F of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4methoxyphenyl)iodonium trifluoromethanesulfonate in CD3CN

54
32. 19F of 3- Fluoro-5-(6-methylpyridine-2-ylethynyl)benzonitrile in CD3CN
33. 1H of 3- Fluoro-5-(6-methylpyridine-2-ylethynyl)benzonitrile in CD3CN
34. 13C of 3- Fluoro-5-(6-methylpyridine-2-ylethynyl)benzonitrile in CD3CN
35. 19F of 3- Fluoro-5-(6-methylpyridine-2-ylethynyl)benzonitrile in CD3CN
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